Our clinical development pipeline features four drug candidates, each with distinct, well defined mechanisms of action for attacking cancers:
Pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare for use in combination with azacitidine for the treatment of patients with newly diagnosed AML who are unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine in patients with high and very high-risk MDS.
ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase Ib study in patients with relapsed/refractory CLL or FL.
Voruciclib, an oral, selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors.
ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer.
For a closer look at our emerging pipeline of drug candidates, please visit our website.
“One of our core strengths at MEI is identifying promising, differentiated oncology drug candidates, applying our drug development expertise to optimize their potential and, ultimately, making a meaningful impact on the lives of cancer patients.”